These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 28842470)

  • 1. IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56
    Dubois S; Conlon KC; Müller JR; Hsu-Albert J; Beltran N; Bryant BR; Waldmann TA
    Cancer Immunol Res; 2017 Oct; 5(10):929-938. PubMed ID: 28842470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion.
    Conlon KC; Potter EL; Pittaluga S; Lee CR; Miljkovic MD; Fleisher TA; Dubois S; Bryant BR; Petrus M; Perera LP; Hsu J; Figg WD; Peer CJ; Shih JH; Yovandich JL; Creekmore SP; Roederer M; Waldmann TA
    Clin Cancer Res; 2019 Aug; 25(16):4945-4954. PubMed ID: 31142503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies.
    Dubois SP; Miljkovic MD; Fleisher TA; Pittaluga S; Hsu-Albert J; Bryant BR; Petrus MN; Perera LP; Müller JR; Shih JH; Waldmann TA; Conlon KC
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imbalance between CD56+bright and CD56+dim natural killer cell subsets in the liver of patients with recurrent hepatitis C after liver transplantation.
    Yamagiwa S; Sato Y; Ichida T; Setsu T; Tominaga K; Kamimura H; Tsuchiya A; Takamura M; Matsuda Y; Aoyagi Y
    Biomed Res; 2014; 35(3):177-84. PubMed ID: 24942856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The biology of human natural killer-cell subsets.
    Cooper MA; Fehniger TA; Caligiuri MA
    Trends Immunol; 2001 Nov; 22(11):633-40. PubMed ID: 11698225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56
    Veneziani I; Alicata C; Pelosi A; Landolina N; Ricci B; D'Oria V; Fagotti A; Scambia G; Moretta L; Maggi E
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD56
    Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
    Front Immunol; 2019; 10():14. PubMed ID: 30761123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential alteration of CD56(bright) and CD56 (dim) natural killer cells in frequency, phenotype, and cytokine response in chronic hepatitis C virus infection.
    Miyagi T; Shimizu S; Tatsumi T; Nishio K; Hiramatsu N; Kanto T; Hayashi N; Takehara T
    J Gastroenterol; 2011 Aug; 46(8):1020-30. PubMed ID: 21559771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD56bright natural killer (NK) cells: an important NK cell subset.
    Poli A; Michel T; Thérésine M; Andrès E; Hentges F; Zimmer J
    Immunology; 2009 Apr; 126(4):458-65. PubMed ID: 19278419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin.
    Batoni G; Esin S; Favilli F; Pardini M; Bottai D; Maisetta G; Florio W; Campa M
    Scand J Immunol; 2005 Dec; 62(6):498-506. PubMed ID: 16316416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis.
    Pierson BA; Miller JS
    Blood; 1996 Sep; 88(6):2279-87. PubMed ID: 8822949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells.
    Juelke K; Killig M; Luetke-Eversloh M; Parente E; Gruen J; Morandi B; Ferlazzo G; Thiel A; Schmitt-Knosalla I; Romagnani C
    Blood; 2010 Aug; 116(8):1299-307. PubMed ID: 20505160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Killer Ig-like receptor (KIR) genotype predicts the capacity of human KIR-positive CD56dim NK cells to respond to pathogen-associated signals.
    Korbel DS; Norman PJ; Newman KC; Horowitz A; Gendzekhadze K; Parham P; Riley EM
    J Immunol; 2009 May; 182(10):6426-34. PubMed ID: 19414796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicobiological, immunophenotypic, and molecular characteristics of monoclonal CD56-/+dim chronic natural killer cell large granular lymphocytosis.
    Lima M; Almeida J; Montero AG; Teixeira Mdos A; Queirós ML; Santos AH; Balanzategui A; Estevinho A; Algueró Mdel C; Barcena P; Fonseca S; Amorim ML; Cabeda JM; Pinho L; Gonzalez M; San Miguel J; Justiça B; Orfão A
    Am J Pathol; 2004 Oct; 165(4):1117-27. PubMed ID: 15466379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/- natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
    Huth TK; Staines D; Marshall-Gradisnik S
    J Transl Med; 2016 Apr; 14():97. PubMed ID: 27098723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue-resident Eomes(hi) T-bet(lo) CD56(bright) NK cells with reduced proinflammatory potential are enriched in the adult human liver.
    Harmon C; Robinson MW; Fahey R; Whelan S; Houlihan DD; Geoghegan J; O'Farrelly C
    Eur J Immunol; 2016 Sep; 46(9):2111-20. PubMed ID: 27485474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation of human natural killer cell phenotypes with age: identification of a unique KLRG1-negative subset.
    Hayhoe RP; Henson SM; Akbar AN; Palmer DB
    Hum Immunol; 2010 Jul; 71(7):676-81. PubMed ID: 20394788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
    Riley CH; Hansen M; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM; Jensen MK
    Eur J Haematol; 2015 Mar; 94(3):227-34. PubMed ID: 25082025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells.
    Takahashi E; Kuranaga N; Satoh K; Habu Y; Shinomiya N; Asano T; Seki S; Hayakawa M
    Scand J Immunol; 2007 Feb; 65(2):126-38. PubMed ID: 17257217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD16- CD56+ natural killer cells after bone marrow transplantation.
    Jacobs R; Stoll M; Stratmann G; Leo R; Link H; Schmidt RE
    Blood; 1992 Jun; 79(12):3239-44. PubMed ID: 1375847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.